Highline Wealth Partners’s Dermata Therapeutics DRMA Stock Holding History

Highline Wealth Partners’s Portfolio DRMA Stock Details DRMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$29	Hold	26	–	–	﹤0.01%	1457
2026 Q2	$34	Buy	+26	New	+$33	﹤0.01%	1403

Other funds holding DRMA

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Highline Wealth Partners's DRMA Position: Q3 2026 in Review

Highline Wealth Partners held its Dermata Therapeutics (DRMA) position steady in Q3 2026 at 26 shares worth $29. The position accounts for ﹤0.01% of the portfolio, ranked #1457.

Highline Wealth Partners first reported a position in DRMA in Q2 2026 and has held it in 2 quarters since. The position peaked at $34 in Q2 2026. 2 funds tracked by Wall St. Rank hold DRMA as of Q3 2026.

Highline Wealth Partners held 26 shares of Dermata Therapeutics worth $29 as of Q3 2026.
Highline Wealth Partners left its Dermata Therapeutics share count unchanged in Q3 2026.
Dermata Therapeutics made up ﹤0.01% of Highline Wealth Partners's portfolio in Q3 2026, its #1457 holding.
Highline Wealth Partners first reported a position in Dermata Therapeutics in Q2 2026 and has held it in 2 quarters since.
Highline Wealth Partners's Dermata Therapeutics position peaked at $34 in Q2 2026.
2 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q3 2026.

Based on Highline Wealth Partners's 13F filing for Q3 2026, filed 19 Oct 2026.